Resources with keywords: Ebola Bundibugyo
Two suspected cases in Italy (travelers from Uganda to Lombardy) ruled out by laboratory testing on 25 May. ECDC assesses EU/EEA HCW and laboratory worker infection risk as very low but not zero. Imported case scenario underscores need for clinical laboratories to maintain front-line screening protocols and for hospital EDs to implement triage-based isolation.
CDC HAN advisory directed at U.S. clinicians, laboratorians, and public health practitioners. CDC issued Level 3 Travel Health Notice for DRC; Level 1 for Uganda. Clinical laboratories instructed to use standard contact and droplet precautions during specimen collection, and to notify public health before processing specimens from febrile patients with relevant travel history. No U.S. cases as of 25 May 2026. One American HCW medically evacuated from DRC to Germany for isolation.
Outbreak originated in a healthcare facility in Mongbwalu Health Zone, Ituri. HCW exposure documented in the index cluster. WHO deploying IPC surge teams. Alert to U.S. hospital infection control teams: any patient presenting with hemorrhagic fever syndrome and travel history to Ituri/N. Kivu requires immediate isolation and notification.
Bundibugyo virus is a BSL-4/Select Agent pathogen with no licensed vaccine or therapeutic. As of 26 May 2026: 105 confirmed + 906 suspected cases; ≥234 deaths in DRC (Ituri, N. Kivu, S. Kivu); 7 confirmed cases in Uganda. Healthcare workers without adequate PPE face high infection risk. U.S. labs handling Ebola must comply with FSAP Tier 1 requirements. All clinical laboratories must implement immediate IPC measures for patients with travel history to DRC/Uganda.
